Abstract
Purpose
DRESS (drug reaction with eosinophilia and systemic symptoms) is an idiosyncratic entity associated with the use of drugs. Its pathophysiology is not known, but is associated with immunological or genetic factors. The incidence is 0.4 cases per 1,000,000 general population. The syndrome usually develops at the beginning of treatment and is characterized by the presence of rash, fever, eosinophilia and systemic manifestations. The aim of our study was to describe the clinical manifestation and treatment of patients with DRESS associated with antiepileptic drugs (AEDs).
Methods
This is a descriptive study with the aim of describing the clinical manifestation and treatment associated with DRESS produced by aromatic and non-aromatic AEDs.
Results
Eight patients treated with AEDs developed DRESS between January 2007 and May 2010 at our hospital. All had dermatological manifestations, eosinophilia and systemic (haematological and hepatic) manifestations that could be attributed to treatment with aromatic AEDs (carbamazepine, 2 patients; lamotrigine, 3 patients; phenytoin, 3 patients). Therapeutic management included removal of the drug from the therapeutic regime, symptomatic management, life support and use of corticosteroids. There was no mortality associated with the syndrome. Reversion of systemic manifestations was very slow: between 1 and 6 months.
Conclusions
DRESS is a severe cutaneous reaction, with high morbidity and mortality, whose development seems to be associated with individual susceptibility, type of antiepileptic drug used (more common with aromatic drugs), titration rate and concomitant medications.
Similar content being viewed by others
Abbreviations
- ADRs:
-
Adverse drug reactions
- AEDs:
-
Antiepileptic drugs
- CBZ:
-
Carbamazepine
- DPH:
-
Phenytoin
- DRESS:
-
Drug reaction with eosinophilia and systemic symptoms
- HHV 6:
-
Human herpes virus 6
- HHV 7:
-
Human herpes virus 7
- LMT:
-
Lamotrigine
- OXC:
-
Oxcarbacepine
- Pb:
-
Phenobarbital
- SCARs:
-
Severe cutaneous adverse reactions
- VPA:
-
Valproic acid
- TPM:
-
Topiramate
References
Perucca E, Meador KJ (2005) Adverse effects of antiepileptic drugs. Acta Neurol Scand 112(Suppl 181):30–35
Zaccara G, Franciotta D, Perucca E (2007) Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48(7):1223–1244
Criado PR, Fachini Jardim Criado R, Vasconcellos C, de Oliveira Ramos R, Gonçalves AC (2004) Severe cutaneous adverse drug reactions - relevant aspects to diagnosis and treatment—Part II. An Bras Dermatol 79(5):587–601, set./out
Li L-F, Ma C (2006) Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 31:642–647
Bouquet H, Bagot M, Roujeau JC (1996) Drug induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinphilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1:250–257
Guidelines for the RegiSCAR Study. September 2009. Available at: http://regiscar.uni-freiburg.de/
Tennis P, Stern RS (1997) Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49:542–546
Roujeau J-C, Stern RS (1994) Severe adverse cutaneous reaction to drugs. N Engl J Med 10:1272–1285
Schlienger RG, Knowles SR, Shear NH (1998) Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 51:1172–1175
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156(3):609–611
Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50
Girolomoni G, Gisondi P, Ottaviani C, Cavani A (2004) Immunoregulation of allergic contact dermatitis. J Dermatol 31(4):264–270
Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK (2003) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63:732–741
Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK (2003) Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 111:1393–1403
Kim C-W, Choi G-S, Yun Chang-Ho, Kim Deok-In (2006) Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome. J Korean Med Sci 21:768–772
Klassen BD, Sadler RM (2001) Induction of hipersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia 42(3):433–435
Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A (2010) Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat 62(1):47–53
Cervigón GI, Sandín SS, Pérez HC, Bahillo MC, Vélez PC, García Almagro D (2006) Síndrome de DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) por sulfonamidas. Med Cutan Iber Lat Am 34(3):120–126
Tohyama M, Yahata Y, Yasukawa M et al (1998) Severe hypersensitivity syndrome due to sulfalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134:1113–1117
Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T (1998) Human herpesvirus 6 infection as a risk factor for the development of severe drug induced hypersensitivity syndrome. Arch Dermatol 134:1108–1112
Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, Beilachs S, Crickx B (2001) Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 137:301–304
Hashimoto K, Yasukawa M, Tohyama M (2003) Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 3:255–260
Pitche P, Padonou CS, Kombate K et al (2005) Stevens–Johnson syndrome and toxic epidermal necrolysis in Lome (Togo). Evolutional and etiological profiles of 40 cases. Ann Dermatol Venereol 132(6–7 Pt 1):531–534
Schopf E, Stuhmer A, Rzany B et al (1991) Toxic epidermal necrolysis and Stevens–Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 127:839–842
Peyrière H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac J-P, Buys DH (2006) Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Therapeutics 155:422–428
Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, y Perucca E, SOPHIE Study Group (2010) Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 51(5):797–804
Centre for Drug Evaluation and Research (CDER) (1997) Glaxo-Wellcome Lamictal Advisory Board Briefing Document, October 23. Glaxo-Wellcome
Guberman A, Besag F, Brodie M, Dooley J, Duchowny M, Pellock J, Richens A, Stern R, Trevathan E (1999) Lamotrigine-associated rash: risk benefit considerations in adults and children. Epilepsia 40(7):985–999, I
Messenheimer J, Mullens EL, Giorgi L, Young F (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18:281–296
Anderson GD (2002) Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43(Suppl 3):53–59
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR Jr (2006) Predictors of Lamotrigine-associated rash. Epilepsia 47:318–322
Fitton A, Goa KL (1995) Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691–713
Federal Drug Administration. Available at: http://www.fda.com
Acknowledgments
Nation Health Ministry. National Commission “Salud Investiga”.
Buenos Aires University. Medicine School.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pereira de Silva, N., Piquioni, P., Kochen, S. et al. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. Eur J Clin Pharmacol 67, 463–470 (2011). https://doi.org/10.1007/s00228-011-1005-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1005-8